The latest update is out from Moleculin Biotech (MBRX).
Moleculin Biotech, Inc. successfully completed a significant public offering, issuing over 2.4 million shares along with Series A and B warrants, at a price of $2.23 each. This move is aimed at raising capital and could be of interest to investors monitoring biotech sector developments and stock market opportunities.
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.